113 related articles for article (PubMed ID: 27059001)
1. Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus.
Jin L; Lim SW; Jin J; Chung BH; Yang CW
Transl Res; 2016 Aug; 174():122-39. PubMed ID: 27059001
[TBL] [Abstract][Full Text] [Related]
2. The effects of addition of coenzyme Q10 to metformin on sirolimus-induced diabetes mellitus.
Sun IO; Jin L; Jin J; Lim SW; Chung BH; Yang CW
Korean J Intern Med; 2019 Mar; 34(2):365-374. PubMed ID: 29228766
[TBL] [Abstract][Full Text] [Related]
3. Effects of metformin on hyperglycemia in an experimental model of tacrolimus- and sirolimus-induced diabetic rats.
Jin J; Lim SW; Jin L; Yu JH; Kim HS; Chung BH; Yang CW
Korean J Intern Med; 2017 Mar; 32(2):314-322. PubMed ID: 27688296
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
Kim SH; Jung E; Yoon MK; Kwon OH; Hwang DM; Kim DW; Kim J; Lee SM; Yim HJ
Eur J Pharmacol; 2016 Oct; 788():54-64. PubMed ID: 27298192
[TBL] [Abstract][Full Text] [Related]
5. Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Endocrine; 2018 Feb; 59(2):383-394. PubMed ID: 29285650
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase IV inhibitor MK-0626 attenuates pancreatic islet injury in tacrolimus-induced diabetic rats.
Jin L; Lim SW; Doh KC; Piao SG; Jin J; Heo SB; Chung BH; Yang CW
PLoS One; 2014; 9(6):e100798. PubMed ID: 24959755
[TBL] [Abstract][Full Text] [Related]
8. Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry.
Kim SH; Lee SH; Yim HJ
Arch Pharm Res; 2013 Oct; 36(10):1185-8. PubMed ID: 23771499
[TBL] [Abstract][Full Text] [Related]
9. Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-L-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes.
Cheng Q; Law PK; de Gasparo M; Leung PS
J Pharmacol Exp Ther; 2008 Dec; 327(3):683-91. PubMed ID: 18787107
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
Kim SJ; Nian C; Doudet DJ; McIntosh CH
Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314
[TBL] [Abstract][Full Text] [Related]
11. Novel culture technique involving an histone deacetylase inhibitor reduces the marginal islet mass to correct streptozotocin-induced diabetes.
Shin JS; Min BH; Lim JY; Kim BK; Han HJ; Yoon KH; Kim SJ; Park CG
Cell Transplant; 2011; 20(9):1321-32. PubMed ID: 21294957
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
Ishibashi K; Hara A; Fujitani Y; Uchida T; Komiya K; Tamaki M; Abe H; Ogihara T; Kanazawa A; Kawamori R; Watada H
Biochem Biophys Res Commun; 2013 Nov; 440(4):570-5. PubMed ID: 24103756
[TBL] [Abstract][Full Text] [Related]
13. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
14. DPP IV inhibitor suppresses STZ-induced islets injury dependent on activation of the IGFR/Akt/mTOR signaling pathways by GLP-1 in monkeys.
Zhang Y; Chen Y; Cheng J; Guo Z; Lu Y; Tian B
Biochem Biophys Res Commun; 2015 Jan; 456(1):139-44. PubMed ID: 25446112
[TBL] [Abstract][Full Text] [Related]
15. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats.
Jin HY; Liu WJ; Park JH; Baek HS; Park TS
Arch Med Res; 2009 Oct; 40(7):536-44. PubMed ID: 20082866
[TBL] [Abstract][Full Text] [Related]
16. Exendin-4 protects hypoxic islets from oxidative stress and improves islet transplantation outcome.
Padmasekar M; Lingwal N; Samikannu B; Chen C; Sauer H; Linn T
Endocrinology; 2013 Apr; 154(4):1424-33. PubMed ID: 23471218
[TBL] [Abstract][Full Text] [Related]
17. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats.
Ávila Dde L; Araújo GR; Silva M; Miranda PH; Diniz MF; Pedrosa ML; Silva ME; de Lima WG; Costa DC
Arch Med Res; 2013 Apr; 44(3):194-202. PubMed ID: 23523961
[TBL] [Abstract][Full Text] [Related]
18. Influence of sirolimus on cyclosporine-induced pancreas islet dysfunction in rats.
Song HK; Han DH; Song JH; Ghee JY; Piao SG; Kim SH; Yoon HE; Li C; Kim J; Yang CW
Am J Transplant; 2009 Sep; 9(9):2024-33. PubMed ID: 19624561
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
Liu Y; Hong T
Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
[TBL] [Abstract][Full Text] [Related]
20. Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury.
Higashijima Y; Tanaka T; Yamaguchi J; Tanaka S; Nangaku M
Am J Physiol Renal Physiol; 2015 Apr; 308(8):F878-87. PubMed ID: 25656369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
